/
Biological products, (no diagnostic substances) company · E9 · FY ends Dec · Revenue $889K · -18959.73% margin · -$150M FCF
The business is unprofitable at the operating level (-18477.83% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1075.0% YoY with margins expanding 223201.1pp.
Negative free cash flow of -$135M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$889K
▲ +1075.0% YoY
Net Income (TTM)
-$72M
▼ -12.7% YoY
Op. Margin
-18959.73%
▲ +223201.1pp YoY
ROIC
-3233.32%
▲ +208.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$150M
▲ +13.2% YoY
Op. Cash Flow (TTM)
-$132M
▲ +4.9% YoY
Net Debt
-$98M
Net Cash Position
Cash & Equiv.
$102M
Continue Research